Shukra Pharmaceuticals Limited (SHUKRAPHAR)

Shukra Pharmaceuticals Limited has submitted its compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The certificate was issued by the company's Registrar and Transfer Agent, Purva Sharegistry (India) Private Limited, on October 1, 2026. It confirms that share certificates received for dematerialisation during the period July 1, 2026, to September 30, 2026, were processed, accepted/rejected, and properly cancelled within prescribed timelines. This is a standard quarterly administrative filing with no impact on the company's financial or operational performance.

• Compliance certificate submitted under Regulation 74(5) for the quarter ended September 30, 2026
• Certificate issued by Registrar and Transfer Agent Purva Sharegistry (India) Pvt. Ltd. dated October 1, 2026
• Covers share certificates processed for dematerialisation between July 1, 2026, and September 30, 2026

Shukra Pharmaceuticals has approved the allotment of 17,35,000 equity shares of face value ₹1 each upon the conversion of warrants by promoters. The company received the remaining 75% balance of ₹26.67 per warrant, aggregating to ₹4.63 crore (total issue price ₹35.56 per share). Following this conversion, promoter holding for Ms. Anar Jayesh Patel and Anar Projects Pvt Ltd increased from 19.70% to 20.01%. All 46,43,000 warrants allotted on January 28, 2026, are now fully converted with zero warrants outstanding.

• Allotment of 17,35,000 equity shares of ₹1 face value upon warrant conversion
• Raised ₹4,62,72,450 (balance 75% at ₹26.67 per warrant) from promoter group
• Paid-up equity share capital expands to ₹44,25,22,440 from ₹44,07,87,440
• Promoter entity holding increased from 19.70% (8,66,00,000 shares) to 20.01% (8,83,35,000 shares)
• Total outstanding convertible warrants reduced to zero

Shukra Pharmaceuticals Limited has announced the results of its Postal Ballot concluded on September 26, 2026. Shareholders approved an amendment to the Object Clause of the Memorandum of Association with 99.9710% votes in favor (1,07,55,536 votes). Additionally, a special resolution to change the company's name to 'Shukra Medtech Limited' was approved with 99.9610% votes in favor (84,75,349 votes). The scrutiny report confirmed that both resolutions were passed with the requisite supermajority.

• Resolution 1 (Object Clause amendment) passed with 99.9710% approval (1,07,55,536 votes in favor vs 3,116 against)
• Resolution 2 (Name change to Shukra Medtech Limited) approved with 99.9610% approval (84,75,349 votes in favor vs 3,303 against)
• Total shareholder count on the August 21, 2026 record date stood at 30,891
• Remote e-voting was conducted from August 28, 2026 to September 26, 2026

Shukra Pharmaceuticals Limited has set Monday, September 21, 2026, as the record date to determine eligibility for a final dividend of ₹0.01 per equity share of face value ₹1 each for FY 2025-26. The dividend proposal is subject to shareholder approval at the company's 33rd Annual General Meeting scheduled for September 28, 2026. If approved, the dividend will be paid within the statutory period to eligible shareholders registered by the record date.

• Final dividend proposed at ₹0.01 per equity share of face value ₹1 each
• Record date fixed as Monday, September 21, 2026
• 33rd Annual General Meeting scheduled for Monday, September 28, 2026

Shukra Pharmaceuticals Limited has issued the notice for its 33rd Annual General Meeting (AGM) scheduled for Monday, September 28, 2026, via Video Conferencing. Key ordinary and special business items include the declaration of a final dividend of ₹0.01 per share (1% on ₹1 face value) for FY26. Shareholders will also vote on the adoption of FY26 audited financial statements, the re-appointment of Ms. Sanskruti Patel as Executive Director, and the regularisation of Mr. Dinesh Chauhan as an Independent Director for 5 years.

• 33rd Annual General Meeting scheduled for Monday, September 28, 2026, at 12:00 PM IST via Video Conferencing.
• Proposed final dividend of 1% (₹0.01 per equity share of face value ₹1) for FY25-26.
• Proposed regularisation of Mr. Dinesh Chauhan as Non-Executive Independent Director for a 5-year term.
• Re-appointment of Ms. Sanskruti Patel as Executive Director retiring by rotation.

Shukra Pharmaceuticals Limited has announced the rescheduling of its 33rd Annual General Meeting (AGM) due to administrative exigencies. The AGM, originally scheduled for September 22, 2026, will now take place on Monday, September 28, 2026, at 12:00 PM IST via video conferencing. Consequently, the revised book closure period is set from September 22, 2026, to September 28, 2026. All other appointments and items approved in the August 22, 2026 board meeting remain unchanged.

• 33rd Annual General Meeting rescheduled from September 22, 2026, to September 28, 2026
• Revised meeting time fixed for 12:00 PM IST through Video Conferencing/OAVM
• Share transfer register and book closure revised to September 22, 2026, through September 28, 2026

Shukra Pharmaceuticals Limited has set Monday, September 21, 2026, as the record date to determine shareholder eligibility for a final dividend. The proposed final dividend is ₹0.01 per equity share of face value ₹1 each for the financial year ended March 31, 2026. The dividend is subject to approval by shareholders at the 33rd Annual General Meeting (AGM) scheduled for Monday, September 28, 2026.

• Proposed final dividend of ₹0.01 per equity share of face value ₹1 each for FY26
• Record date fixed as Monday, September 21, 2026
• 33rd Annual General Meeting (AGM) scheduled for Monday, September 28, 2026

Shukra Pharmaceuticals has approved the allotment of 11,73,000 equity shares of face value Re 1 each to promoter entity Navkar Surgical Gujarat Limited following the conversion of warrants. The allotment was executed upon receipt of the remaining 75% exercise price of Rs 26.67 per warrant, aggregating to Rs 3,12,83,910 (Rs 3.13 crore) against the total issue price of Rs 35.56 per share. Consequently, the company's paid-up share capital increased from Rs 43.96 crore to Rs 44.08 crore. A balance of 17,35,000 warrants remains outstanding for conversion within the 18-month tenure from January 28, 2026.

• Allotted 11,73,000 equity shares of Re 1 face value upon warrant conversion to promoter entity Navkar Surgical Gujarat Limited.
• Raised Rs 3,12,83,910 (Rs 3.13 crore) upon receiving the balance 75% payment of Rs 26.67 per warrant.
• Total paid-up share capital expanded to Rs 44,07,87,440 comprising 44,07,87,440 equity shares.
• Promoter entity's stake increased from 11.78% (5.16 crore shares) to 11.93% (5.28 crore shares).
• 17,35,000 warrants remain outstanding for conversion out of 46,43,000 originally allotted on January 28, 2026.

Shukra Pharmaceuticals Limited has issued a Postal Ballot notice seeking shareholder approval via special resolutions to alter its Memorandum of Association (MoA) Object Clause and change the company name to 'Shukra Medtech Limited'. The proposed MoA amendment enables entry into medical devices, surgical robotics, AI-driven healthcare technologies, diagnostics, and MedTech parks. The remote e-voting period runs from August 28, 2026 (9:00 AM) to September 26, 2026 (5:00 PM).

• Remote e-voting starts on August 28, 2026 (9:00 AM) and closes on September 26, 2026 (5:00 PM)
• Proposed change of company name from 'Shukra Pharmaceuticals Limited' to 'Shukra Medtech Limited'
• MoA Clause III(A) alteration to include sub-clauses (2) to (7) covering medical devices, diagnostics, AI healthcare, and MedTech infrastructure
• MCA approval for name availability received on August 14, 2026

Shukra Pharmaceuticals Limited's Board has approved altering its Memorandum of Association (MOA) to expand into medical devices, robotic surgical systems, AI healthcare tech, and MedTech parks. In alignment with this strategic shift, the company proposed changing its name to 'Shukra Medtech Limited', subject to regulatory and shareholder approvals via postal ballot. Additionally, the company scheduled its 33rd Annual General Meeting (AGM) for September 25, 2026, with share transfer books closed from September 19 to September 25, 2026.

• Board approved changing company name from 'Shukra Pharmaceuticals Limited' to 'Shukra Medtech Limited'
• MOA Main Objects Clause amended to add 6 new sub-clauses covering medical devices, surgical robotics, AI healthcare, and MedTech parks
• 33rd Annual General Meeting scheduled for September 25, 2026 via Video Conferencing
• Book closure period set from September 19, 2026 to September 25, 2026 (both days inclusive)

Shukra Pharmaceuticals has issued a clarification regarding recent media reports discussing its strategic focus on Medical Technology and Artificial Intelligence. The company stated that the media coverage following its NSE listing on August 14, 2026, outlines general strategic direction and does not represent any new material contracts, orders, acquisitions, or investments. The company's shares are now listed and actively traded on both BSE and NSE.

• Equity shares listed and commenced trading on the National Stock Exchange on August 14, 2026.
• Company shares are now dual-listed and actively traded on BSE (524632) and NSE (SHUKRAPHAR).
• Clarified that ANI media report published on August 14, 2026, does not involve any new material commercial transactions.